MIM
XFOR icon

MetLife Investment Management’s X4 Pharmaceuticals XFOR Stock Holding History

MetLife Investment Management’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,181
Closed -$71.3K – 2868
2023
Q3 		$71.3K Hold
2,181
– – ﹤0.01% 2753
2023
Q2 		$127K Buy
+2,181
New +$112K ﹤0.01% 2539

Other funds holding XFOR

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

MetLife Investment Management's XFOR Position: Q4 2023 in Review

MetLife Investment Management sold out of X4 Pharmaceuticals (XFOR) in Q4 2023, closing a stake of 2,181 shares — an estimated $71.3K sold.

MetLife Investment Management first reported a position in XFOR in Q2 2023 and held it in 2 quarters. The position peaked at $127K in Q2 2023. 93 funds tracked by Wall St. Rank hold XFOR as of Q4 2023.

  • MetLife Investment Management reported no remaining X4 Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • MetLife Investment Management sold 2,181 X4 Pharmaceuticals shares in Q4 2023, an estimated $71.3K.
  • MetLife Investment Management first reported a position in X4 Pharmaceuticals in Q2 2023 and held it in 2 quarters.
  • MetLife Investment Management's X4 Pharmaceuticals position peaked at $127K in Q2 2023.
  • 93 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q4 2023.

Based on MetLife Investment Management's 13F filing for Q4 2023, filed 14 Feb 2024.